Dosing Equivalency Unknown: There is no established conversion factor between oral and injectable dosing based on human clinical trials
The 2D MOF shows negligible toxicity in M1 macrophages even in 48 h of co-incubation, as determined by cell counting kit-8 (CCK-8) assay (Fig
metabolite Ac-LKKTE identified as potentially more active than parent compound Paradoxical finding: Both peptides show biological effects persisting hours to days after administration despite rapid plasma clearance Possible explanations: Tissue retention, active metabolites, or persistent signaling cascade activation Excretion Pathways Limited data exists on excretion for both peptides[22]: Likely renal elimination of peptide fragments Hepatic metabolism may contribute to clearance No accumulation detected in chronic dosing studies (animal models) Combined excretion kinetics have not been characterized in any species The disconnect between short plasma half-lives and prolonged biological effects represents a key area requiring mechanistic clarification for both individual peptides and their combination
Oral administration is the most logical route for gut-focused applications, since the peptide is uniquely stable in gastric juice
Only advanced or anti-doping tests are designed to identify specific peptides or performance-enhancing compounds
McKinnon JE, Santiaguel J, Murta de Oliveira C, Yu D, Khursheed M, Moreau F, et al
